CANNABINOID BIOSYNTHESIS :
Growing
Cannabinoids Without the Plant
When it comes to cost-effective cannabinoid production , Biomedican is on the right track using yeast to create cannabinoids in a lab at a fraction of the cost compared to commercial field / greenhouse plant production . by Lee Allen
Faster . Cheaper . Sustainable .
Biomedican employees must feel they ’ re three-for-three in that race following the recent announcement of a unique method of cannabinoid biosynthesis production that produces high-quality rare cannabinoids — in the laboratory — with nary a plant in sight . “ At the end of the day , our molecule is identical to that of the natural world ,” says co-founder Dennis O ’ Neill , an investment banker . “ We ’ re a biotech , life sciences company focused on producing rare cannabinoids and terpenes , but made with yeasts rather than from an actual plant .” It ’ s like bacon slices without the pig or chicken wings without the chicken : creating a plant compound — cannabinoids — without the usual cannabis plant . No seeding , growing , or harvesting ; just tending proprietary yeast . It ’ s a multi-step process called biosynthesis that emulates living organisms producing essential compounds , converting the simple into the more complex .
“ If you ’ re in the farming business , every plant is a bit different and you have to deal with drought and toxins and contaminants and things of that sort . We ’ re able to deliver a better product that is typically about 75-90 percent cheaper to produce than anybody else in the market today . Ultimately , we ’ re going to be able to create all these rare cannabinoids for less than a dollar per gram .”
Asked if this was ‘ better living through chemistry ’, O ’ Neill says : “ Our molecule is organic , non-GMO , and doesn ’ t produce THC at any point in time , putting us outside federal regulation .
“ Folks will still smoke field-grown cannabis and there ’ s a lot of involvement with CBD , but we ’ re not focused on those . We ’ re focused on the finite trace amounts of rare cannabinoids in our process rather than having to grow a hundred thousand acres of product just to come up with enough supply of some of these trace amounts to make things beneficial . That way is just not cost-effective . Our way is to come up with significant medical benefits at very , very low cost .”
94 Maximum Yield